| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Departments of Urology, Pathology, and Laboratory Medicine, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA;
Centre for Urological Research, Monash Institute of Medical Research, Monash University, Clayton, Australia;
Departments of Anatomy and Urology, University of California, San Francisco, California, USA; and
Department of Cancer Endocrinology and The Prostate Center, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
1Correspondence: University of Rochester, Department of Urology, 601 Elmwood Ave., Box 656, Rochester, NY 14642, USA. E-mail: william_ricke{at}urmc.rochester.edu
It was recently demonstrated that antiestrogens prevented prostate cancer (PRCA) in men. The source of estradiol (E2) that contributes to carcinogenesis, as well as the selected estrogen receptor (ER) signaling pathway, is unknown. To evaluate estrogen’s effects in carcinogenesis, we developed a new model of PRCA utilizing testosterone and E2 to stimulate PRCA. To determine whether local in situ production of E2 affected incidence of PRCA, aromatase-knockout (ArKO) mice were evaluated. In contrast to the wild-type mice, ArKO mice had reduced incidences of PRCA, which implicates in situ production of E2 as an important determinant of PRCA. To determine whether E2-mediated responses were due to ER
or ERβ signaling, ER-knockout (ERKO) or ERβ-knockout (βERKO) mice were used. Prostates from βERKO mice underwent biochemical and histological carcinogenesis similar to wild-type mice, whereas prostates from ERKO mice remained free of pathology. These data suggest that effective prevention of carcinogenesis will require antagonism of ER but not ERβ. This mouse model provides a means to examine genetic gain and loss of function and determine the efficacy of therapeutics on prostatic carcinogenesis.—Ricke, W. A., McPherson, S. J., Bianco, J. J. Cunha, G. R., Wang, Y., Risbridger, G. P. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling.
Key Words: prostate cancer • hormone action • mouse models
Related Article
FASEB J 2009 23: 1285-1286.
This article has been cited by other articles:
|
|
 |
|
  U. Simanainen, K. McNamara, Y. R. Gao, and D. J. Handelsman Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1335 - E1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Friedman Regarding "Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling" FASEB J, May 1, 2009; 23(5): 1285 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chen, I. Hsu, A. Wolfe, S. Radovick, K. Huang, S. Yu, C. Chang, E. M. Messing, and S. Yeh Defects of Prostate Development and Reproductive System in the Estrogen Receptor-{alpha} Null Male Mice Endocrinology, January 1, 2009; 150(1): 251 - 259. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
